Trial reportBMC research notes2021
A pilot trial of human amniotic fluid for the treatment of COVID-19.
Trial report in BMC research notes, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04319731 (A Pilot Study of Human Amniotic Fluid for COVID19 Associated Respiratory Failure), which is not on this map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Pilot Study of Human Amniotic Fluid for COVID19 Associated Respiratory Failure
Who cites it
8 citing papers in PubMed, 14 citations in OpenAlex.
- A randomized, double-blinded, placebo-controlled clinical trial of sterile filtered human amniotic fluid for treatment of COVID-19.BMC infectious diseases · 2023Trial
- Intravenous acellular human amniotic fluid prevents ischemic cardiac remodeling.Scientific reports · 2025Article
- Article
- Immersed in a reservoir of potential: amniotic fluid-derived extracellular vesicles.Journal of translational medicine · 2024Review
- Cell-Free Amniotic Fluid and Regenerative Medicine: Current Applications and Future Opportunities.Biomedicines · 2022Review
- Article
- Chick early amniotic fluid component improves heart function and protects against inflammation after myocardial infarction in mice.Frontiers in cardiovascular medicine · 2022Article
- Passive Immunity Should and Will Work for COVID-19 for Some Patients.Clinical hematology international · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveVertical transmission from SARS CoV-2-infected women is uncommon and coronavirus has not been detected in amniotic fluid. Human amniotic products have a broad immune-mediating profile. Observing that many COVID-19 patients have a profound inflammatory response to the virus, we sought to determine the influence of human amniotic fluid (hAF) on hospitalized patients with COVID-19.
resultsA 10-patient case series was IRB-approved to study the impact of hAF on hospitalized patients with documented COVID-19. Nine of the 10 patients survived to discharge, with one patient succumbing to the disease when enrolled on maximal ventilatory support and severe hypoxia. The study design was altered by the IRB such that the last 6 patients received higher dose of intravenous hAF. In this latter group, patients that had observed reductions in C-reactive protein were associated with improved clinical outcomes. No hAF-related adverse events were noted. Acknowledging some of the inherent limitations of this case series, these results inform and catalyze a larger scaled randomized prospective trial to further investigate hAF as a therapy for COVID-19. Trial Registration ClinicalTrials.gov: NCT04319731; March 23, 2020.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.